Literature DB >> 25540209

A diagnosis of haemolytic-uraemic syndrome blurred by alcohol abuse.

Martin Killian1, Noémie Bruel Tronchon2, Nicolas Maillard3, Bernard Tardy2.   

Abstract

A 60-year-old man with a history of alcohol abuse was admitted to the intensive care unit (ICU) for status epilepticus. At first, laboratory and imagery findings were almost normal, and the symptoms were attributed to severe alcohol withdrawal due to a history of gastroenteritis reported by his family. But, during the following days, haemolytic anaemia, thrombocytopenia, acute renal failure, and ischaemic and haemorrhagic lesions seen on a cerebral CT scan led to the diagnosis of haemolytic-uraemic syndrome (HUS). Despite these severe complications, the patient made a good recovery following ICU and plasma exchange with fresh frozen plasma (FFP), but cognitive deficit still existed after 1 month. It is important to know that neurological manifestations can precede typical biological and radiological signs in HUS, and to not be misled in the diagnosis process, especially when a more common differential diagnosis is possible. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25540209      PMCID: PMC4281547          DOI: 10.1136/bcr-2014-205940

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak.

Authors:  S Dundas; J Murphy; R L Soutar; G A Jones; S J Hutchinson; W T Todd
Journal:  Lancet       Date:  1999-10-16       Impact factor: 79.321

2.  The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak.

Authors:  Tim Magnus; Joachim Röther; Olga Simova; Maria Meier-Cillien; Jonas Repenthin; Fabian Möller; Joystone Gbadamosi; Ulf Panzer; Martina Wengenroth; Christian Hagel; Stefan Kluge; Rolf K Stahl; Karl Wegscheider; Peter Urban; Bernd Eckert; Markus Glatzel; Jens Fiehler; Christian Gerloff
Journal:  Brain       Date:  2012-04-26       Impact factor: 13.501

Review 3.  Diarrhoeagenic Escherichia coli--an emerging problem?

Authors:  S C Clarke
Journal:  Diagn Microbiol Infect Dis       Date:  2001-11       Impact factor: 2.803

4.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

Review 5.  Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome.

Authors:  P E Ray; X H Liu
Journal:  Pediatr Nephrol       Date:  2001-10       Impact factor: 3.714

Review 6.  Escherichia coli O157:H7: etiology, clinical features, complications, and treatment.

Authors:  E Peacock; V W Jacob; S M Fallone
Journal:  Nephrol Nurs J       Date:  2001-10       Impact factor: 0.959

Review 7.  First seizure definitions and worldwide incidence and mortality.

Authors:  W Allen Hauser; Ettore Beghi
Journal:  Epilepsia       Date:  2008       Impact factor: 5.864

8.  Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome.

Authors:  Angela Bauer; Sebastian Loos; Carola Wehrmann; Dirk Horstmann; Frank Donnerstag; Johanna Lemke; Georg Hillebrand; Ulrike Löbel; Lars Pape; Dieter Haffner; Carola Bindt; Thurid Ahlenstiel; Anette Melk; Anja Lehnhardt; Markus J Kemper; Jun Oh; Hans Hartmann
Journal:  Pediatr Nephrol       Date:  2014-03-25       Impact factor: 3.714

Review 9.  Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.

Authors:  Mini Michael; Elizabeth J Elliott; Greta F Ridley; Elisabeth M Hodson; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

10.  Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.

Authors:  Angela Gerber; Helge Karch; Franz Allerberger; Hege M Verweyen; Lothar B Zimmerhackl
Journal:  J Infect Dis       Date:  2002-08-02       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.